This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Gabapentin on Idiopathic Subjective Tinnitus

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2008 by Islamic Azad University of Mashhad.
Recruitment status was:  Active, not recruiting
Information provided by:
Islamic Azad University of Mashhad Identifier:
First received: November 8, 2007
Last updated: January 5, 2009
Last verified: August 2008
The purpose of this study is to determine wether Gabapentin which is useful for treating neuropathic pains, is effective on idiopathic subjective tinnitus.

Condition Intervention Phase
Subjective Tinnitus Drug: Gabapentin Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 2 Effect of Gabapentin on Idiopathic Subjective Tinnitus

Resource links provided by NLM:

Further study details as provided by Islamic Azad University of Mashhad:

Primary Outcome Measures:
  • Reduction in the sensation of Tinnitus by the patient or complete resolution of tinnitus;by the patient's scoring it from one to ten, before and after prescribing Gabapentin. [ Time Frame: two months ]

Secondary Outcome Measures:
  • Relieve of complications of tinnitus, such as sleep difficulties. [ Time Frame: two months ]

Estimated Enrollment: 70
Study Start Date: January 2007
Estimated Study Completion Date: October 2008
Estimated Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Randomly,half of the subjects are given Gabapentin.
Drug: Gabapentin
Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.
Other Name: Neurontine
Placebo Comparator: 2
Randomly,half of the subjects receive placebo.
Drug: placebo
placebo is given with the same definition as Gabapentin

Detailed Description:

Tinnitus is the perception of sound in the absence of acoustic stimulation. It can be subjective or objective. .

Despite numerous researches,no effective treatment for people who suffer from tinnitus has yet been stablished.

As there are many evidences suggesting that loss of inhibition in the central nervous system may be responsible for many aspects of auditory dysfunction,including tinnitus; and as Gabapentin (Neurontin), a gama-aminobutyric acid (GABA) analogue, is an effective medication in conditions where inhibition in the CNS is impaired; we guess that Gabapentin might be useful for treating idiopathic subjective tinnitus.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with subjective idiopathic tinnitus

Exclusion Criteria:

  • tinnitus with known underlying cause
  • pregnant women and patients younger than 18 or older than 75 years
  • patients with impaired renal function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00555776

Iran, Islamic Republic of
ENT department of Mashhad Azad medical university
Mashhad, Khorasan razavi, Iran, Islamic Republic of, 91786 56553
Sponsors and Collaborators
Islamic Azad University of Mashhad
Principal Investigator: Mahboobeh Adami Dehkordi, MD ENT department of Mashhad azad university of mashhad
  More Information

Responsible Party: Dr.Mahboobeh Adami Dehkordi, Assisstant professor Identifier: NCT00555776     History of Changes
Other Study ID Numbers: Gaba-tinntus-145
Study First Received: November 8, 2007
Last Updated: January 5, 2009

Keywords provided by Islamic Azad University of Mashhad:

Additional relevant MeSH terms:
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
gamma-Aminobutyric Acid
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Antimanic Agents
GABA Agents processed this record on August 18, 2017